Currently, five tyrosine kinase inhibitors (TKIs—imatinib, dasatinib, nilotinib, bosutinib, and asciminib) are available for frontline therapy, but no single TKI is optimal for all patients. EUTOS ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

suggest that patients with a type of blood cancer called chronic lymphocytic leukemia (CLL) who are being treated with Bruton's tyrosine kinase inhibitors (BTKi), should continue their therapy ...

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Blood cancer patients who receive a type of anti-cancer therapy should ... More information: A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination ...